Recombinant Human CSF1R, Fc-His tagged

• Cat.No.: CSF1R-39H
• Product Overview: Recombinant Human CSF1R precursor extracellular domain (Met 1-Glu512) (NP_005202.2), fused with the polyhistidine-tagged Fc region of human IgG1 at the C-terminus, was produced in Human Cell.

Specification

• Source: Human Cells
• Species: Human
• Tag: His&Fc
• Form: Lyophilized from sterile PBS, pH 7.4
• Molecular Mass: The recombinant human M-CSFR/Fc chimera is a disulfide-linked homodimer protein. The monomeric subunit contains 737 amino acids after the removal of signal peptide with a calculated molecular mass of 82.4 kDa. As a result of glycosylation, the monomer migrates as an approximately 115-125 kDa protein in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Stability: Samples are stable for up to twelve months from date of receipt at -70oC.
• Storage: Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: CSF1R colony stimulating factor 1 receptor [ Homo sapiens ]
• Official Symbol: CSF1R
• Gene ID: 1436
• mRNA Refseq: NM_005211
• Protein Refseq: NP_005202
• MIM: 164770
• UniProt ID: P07333

Reviews

01/09/2022

With its remarkable quality, reliability, and the manufacturer's excellent technical support, I am confident that it will be an invaluable asset in driving my scientific inquiries forward and facilitating groundbreaking discoveries in my field.

10/30/2017

This variety allows me to select the most appropriate option based on the specific requirements of my research.

03/10/2017

the manufacturer's commitment to quality control and rigorous testing guarantees the reliability and reproducibility of the CSF1R protein, which is essential for obtaining accurate and consistent results.

Q&As

Are there any FDA-approved drugs targeting CSF1R for clinical use?

Yes, drugs like pexidartinib have been approved for the treatment of certain rare tumors called tenosynovial giant cell tumors (TGCT) that overexpress CSF1R.

How can CSF1R inhibitors impact the tumor microenvironment?

CSF1R inhibitors can modulate the tumor microenvironment by reducing the number of tumor-associated macrophages and promoting an anti-tumor immune response.

Can CSF1R inhibitors be used in combination with other cancer treatments?

Yes, CSF1R inhibitors are often used in combination with chemotherapy and immunotherapy to enhance treatment effectiveness.

What are the potential clinical applications of CSF1R inhibitors?

CSF1R inhibitors are being investigated for cancer therapy to block tumor-promoting macrophages and slow down cancer progression.

Can CSF1R inhibitors be used to treat neurodegenerative diseases?

Research is ongoing, and CSF1R inhibitors are being explored as a potential therapy for neurodegenerative diseases, but no FDA-approved treatments currently exist.